Amylyx Pharmaceuticals, Inc. (AMLX) Return on equity 2022–2025
Amylyx Pharmaceuticals, Inc. (AMLX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-47.4%FY2025 · since FY2022: -58.2% → -47.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -47.4% | +135.7 pp |
| FY2024 | -183.1% | -194.5 pp |
| FY2023 | 11.4% | +69.6 pp |
| FY2022 | -58.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AMLX financial trends
AMLX RevenueAMLX Net incomeAMLX Net marginAMLX Gross profitAMLX Gross marginAMLX Operating incomeAMLX Operating marginAMLX Operating cash flowAMLX Free cash flowAMLX Capital expendituresAMLX Stock buybacksAMLX Dividends paidAMLX Total assetsAMLX Total liabilitiesAMLX Shareholders’ equityAMLX overview →